BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 18156463)

  • 1. Identification and design of peptides as a new drug delivery system for the brain.
    Demeule M; Régina A; Ché C; Poirier J; Nguyen T; Gabathuler R; Castaigne JP; Béliveau R
    J Pharmacol Exp Ther; 2008 Mar; 324(3):1064-72. PubMed ID: 18156463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Trojan horses for blood-brain barrier drug delivery.
    Pardridge WM
    Curr Opin Pharmacol; 2006 Oct; 6(5):494-500. PubMed ID: 16839816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer.
    Ke W; Shao K; Huang R; Han L; Liu Y; Li J; Kuang Y; Ye L; Lou J; Jiang C
    Biomaterials; 2009 Dec; 30(36):6976-85. PubMed ID: 19765819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases.
    Gabathuler R
    Neurobiol Dis; 2010 Jan; 37(1):48-57. PubMed ID: 19664710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2.
    Demeule M; Currie JC; Bertrand Y; Ché C; Nguyen T; Régina A; Gabathuler R; Castaigne JP; Béliveau R
    J Neurochem; 2008 Aug; 106(4):1534-44. PubMed ID: 18489712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of peptides to the brain: emphasis on therapeutic development.
    Banks WA
    Biopolymers; 2008; 90(5):589-94. PubMed ID: 18335425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High transcytosis of melanotransferrin (P97) across the blood-brain barrier.
    Demeule M; Poirier J; Jodoin J; Bertrand Y; Desrosiers RR; Dagenais C; Nguyen T; Lanthier J; Gabathuler R; Kennard M; Jefferies WA; Karkan D; Tsai S; Fenart L; Cecchelli R; Béliveau R
    J Neurochem; 2002 Nov; 83(4):924-33. PubMed ID: 12421365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier.
    Lu W; Tan YZ; Hu KL; Jiang XG
    Int J Pharm; 2005 May; 295(1-2):247-60. PubMed ID: 15848009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization, receptor mapping and blood-brain barrier transcytosis of antibodies to the human transferrin receptor.
    Friden PM; Olson TS; Obar R; Walus LR; Putney SD
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1491-8. PubMed ID: 8819537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 2. Cationic peptide vectors for brain delivery.
    Adenot M; Merida P; Lahana R
    Chemotherapy; 2007; 53(1):73-6. PubMed ID: 17202815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs.
    Cucullo L; Hossain M; Rapp E; Manders T; Marchi N; Janigro D
    Epilepsia; 2007 Mar; 48(3):505-16. PubMed ID: 17326793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo biodistribution of prion- and GM1-targeted polymersomes following intravenous administration in mice.
    Stojanov K; Georgieva JV; Brinkhuis RP; van Hest JC; Rutjes FP; Dierckx RA; de Vries EF; Zuhorn IS
    Mol Pharm; 2012 Jun; 9(6):1620-7. PubMed ID: 22536790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retro-inverso isomer of Angiopep-2: a stable d-peptide ligand inspires brain-targeted drug delivery.
    Wei X; Zhan C; Chen X; Hou J; Xie C; Lu W
    Mol Pharm; 2014 Oct; 11(10):3261-8. PubMed ID: 24673510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2B-Trans technology: targeted drug delivery across the blood-brain barrier.
    Gaillard PJ; de Boer AG
    Methods Mol Biol; 2008; 437():161-75. PubMed ID: 18369968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood-brain barrier delivery.
    Pardridge WM
    Drug Discov Today; 2007 Jan; 12(1-2):54-61. PubMed ID: 17198973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration.
    Ché C; Yang G; Thiot C; Lacoste MC; Currie JC; Demeule M; Régina A; Béliveau R; Castaigne JP
    J Med Chem; 2010 Apr; 53(7):2814-24. PubMed ID: 20210346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity.
    Rousselle C; Smirnova M; Clair P; Lefauconnier JM; Chavanieu A; Calas B; Scherrmann JM; Temsamani J
    J Pharmacol Exp Ther; 2001 Jan; 296(1):124-31. PubMed ID: 11123372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of nose-to-brain homing peptide through phage display.
    Wan XM; Chen YP; Xu WR; Yang WJ; Wen LP
    Peptides; 2009 Feb; 30(2):343-50. PubMed ID: 19007831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Strategies for drug delivery to the brain across the blood-brain barrier].
    Tsuji A
    Nihon Rinsho; 1998 Mar; 56(3):613-8. PubMed ID: 9549345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to deliver peptide drugs to the brain.
    Lalatsa A; Schatzlein AG; Uchegbu IF
    Mol Pharm; 2014 Apr; 11(4):1081-93. PubMed ID: 24601686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.